<DOC>
	<DOCNO>NCT00349037</DOCNO>
	<brief_summary>The purpose study evaluate effective vaccine prevent subject develop flu symptom directly expose flu virus . The study also evaluate well vaccine tolerate site administration give , effect may subject ' wellbeing whether produce antibody responses body</brief_summary>
	<brief_title>Study Ability Flu Vaccine Prevent Flu Infection</brief_title>
	<detailed_description>Influenza contagious disease upper airways lung . It rapidly spread around world seasonal epidemic , kill hundred thousand people high economic consequence due healthcare cost lose productivity . Each year government recommend group risk influenza complication receive influenza vaccination . Current vaccine supply sufficient meet demand recommendation take . This study evaluate PowderMed 's Particle Mediated Epidermal Delivery ( PMED ) DNA vaccine influenza potential alternative exist vaccine technology . This study assess effective two different PMED vaccine combination prevent subject develop influenza follow exposure flu virus 56 day single dose vaccine .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult volunteer ( woman must non childbearing potential ) Provided write informed consent No significant concomitant illness No allergy gold No immunosuppression due disease treatment Preexisting protective level antibody challenge virus strain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>DNA vaccine</keyword>
	<keyword>influenza</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>tolerability</keyword>
	<keyword>PMED</keyword>
	<keyword>efficacy</keyword>
	<keyword>challenge virus</keyword>
</DOC>